BIOTECHNOLOGY INDUSTRY

VIVEKRAJ S N (10AB45)

SIDDARTH VARSHAN(10AB35)

APARNA V(10AB04)

RANJANA KRISHNAN(10AB26)

SANGEETHA PRIYA U (10AB30)

Biotechnology is a field of applied biology that involves the use of living organisms and bioprocesses in engineering, technology, medicine and other fields requiring bio-products.

The United Nations Convention on Biological Diversity defines biotechnology as:"Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use."

INTRODUCTION

Biotechnology draws on the pure biological sciences (genetics, microbiology, animal cell culture, molecular

biology, biochemistry, embryology, cell biology) also dependent on knowledge and methods from outside the

sphere of biology. (chemical engineering, bioprocess engineering, information

technology, biorobotics).

CONTD…

drugs.The good and bad kind !malnutrition and famine. Many mouths,

little land !Beer is good- drink more- boiotech thanks

you !1978- The magic bullet for diabetes.80s era- sunshine industry

HISTORY OF BIOTECHNOLOGY

In 1988, only 5 proteins from genetically engineered cells had been approved as drugs by the United States Food and Drug Administration (FDA), but this number skyrocketed to over 125 by the end of the 1990s.

While it seems only natural nowadays to link pharmaceutical drugs as solutions to health and societal problems, this relationship of biotechnology serving social needs began centuries ago.

With ancestral roots in industrial microbiology that date back centuries, the biotechnology industry grew rapidly beginning in the mid-1970s.

CONTD…

Genetic engineering in biotechnology stimulated hopes for both therapeutic proteins and drugs and biological organisms themselves, such as seeds, pesticides, engineered yeasts, and modified human cells for treating genetic diseases.

From the perspective of its commercial promoters, scientific breakthroughs, industrial commitment, and official support were finally coming together, and biotechnology became a normal part of business.

CONTD…

SWOT Analysis

Highly skilled and qualified scientific manpower Government taking initiatives to support biotech sector Capability in handling fermentation based compounds,

extraction of high quality products using plant and animal parts.

plant breeding techniques, plant cell/tissue culture, bioprocess engineering, use of cell/microbial culture techniques, etc

Effective and efficient biotech enterprises. Infrastructure in manufacturing processing equipments

and bio-reactors

STRENGTHS

Administration of resources supporting biotech research and development

Lack of awareness regarding biotech practices Missing link between research and commercialisation. Lack of venture capital Relatively low R&D expenditure by industry Image of Indian industry -doubts about ability of Indian

products to meet international standards of quality

WEAKNESS

Large market Export potential Base for contract research for international companies

due to rising costs of R&D abroad. Large number of patients covering wider range of

diseases

OPPURTUNITIES

Lack of advanced biotechnologies and products Lack of public awareness about biotechnology issues Difference between theory and practice in R&D Danger of anti-biotech propaganda gaining ground

THREATS

Panacea Biotec Ltd has bagged a three-year contract worth over US$ 222.37 million from UNICEF to provide the agency with EasyFive vaccine, a protection against a set of pediatric diseases for 2010, 2011 and 2012.

Alexandria Real Estate, the US$ 5.2 billion US-based company which provides solutions to life science industry, has decided to set up a biotech research and development (R&D) and incubation facility in Gujarat. It plans to spend around US$ 107 million for the project.

MAJOR INVESTMENTS

The Defence Research and Development Organisation (DRDO), which caters primarily to the armed forces, plans to spend US$ 63.5 million to upgrade and custom-make its existing line of biotech products for civilian use.

Biotechnology major Biocon has fully acquired the joint venture Biocon Biopharmaceuticals from its Cuban partner CIMAB. Under the business restructuring plan, Biocon will pick up CIMAB's 49 per cent stake and will make Biocon Biopharmaceuticals (BBPL) a wholly owned subsidiary of Biocon.

CONTD…

PEST ANALYSIS

Commercial cultivation of BT cotton was approved by the government in early 2002 which today accounts for about 70 per cent of the total area under cotton cultivation and thus makes agri-biotech the fastest growing biotech industry.

The government has announced a National Biotechnology Policy as recognition of the importance of the sector as a key growth area. The key elements of strategy include:

(i)Set up of a National Biotechnology Regulatory Authorit (ii) A high-powered Inter-ministerial Committee is to be set up under

the chairmanship of secretary, DBT, to effectively coordinate the development of the sector by addressing cross cutting issues.

(iii) 30 percent of DBT's Budget to be spent on public-private partnership programs.

POLITICAL

(iv) A Biotechnology Industry Partnership Programme (BIPP) for Advanced Technology would be launched.

(v) The existing Small Business Innovation Research Industry (SBIRI) scheme to promote innovation in SMEs has been a success.

Biotech Parks: The government has set up exclusive Biotech Parks such as Shapoorji Pallonji Biotech Park, Hyderabad; ICICI Knowledge Park, Hyderabad; International Biotech Park, Pune. These biotechnology parks are acting as bioclusters - where companies, universities and R&D institutes are all located in one place.

CONTD…

Market Trends: India is ranked among the top 12 biotech destinations in the world and the

Indian biotech sector is the third largest in the Asian region after Australia and China.

The Indian biotechnology sector has excellent potential and is expected to touch five billion-dollar mark by 2010.

The biotechnology sector in India is growing rapidly at a rate of over 40 percent annually. India is the largest producer of recombinant Hepatitis B vaccine in the world.

India occupies a significant position in the world pharma market, 8% by volume

(fourth largest in the world) and 1% by value. The pharma industry ranks 17th in

terms of export value. India accounts for 22% of the global generics market

ECONOMIC

Biopharmaceuticals: This constitutes the largest segment of the Indian biotech industry both in terms of domestic and export revenues. About 70 percent of the domestic biotech industry comprises of the Biopharma sector. Of the total 325 biotechnology companies in India, more than 40 percent are in the biopharma sector. Vaccines, therapeutics and diagnostics fall into this category.

BioServices: The Bioservices market is the second largest sector of the Indian Biotechnology Industry. The market’s growth can be attributed to the fact that India has become a popular destination for clinical trial, contract research and manufacturing activities.

Agricultural Biotechnology: This segment can be segmented into Hybrid seeds and transgenic crops, Biopesticides and Biofertilizers. Genetically modified cotton or commonly known as Bt cotton constitutes approximately 77 percent of the revenue of this sector whereas Biopesticides and biofertilizers together account only for 23 percent of the revenues garnered by agricultural biotechnology.

SOCIAL

BioInformatics / BioIT: This sector deals with the creation and maintenance of extensive electronic databases on various biological systems and is probably the smallest part of the current domestic biotechnology industry. However, India is known for its strong IT base and it is due to this that India is sure to become a leading destination for work in the bioinformatics arena.

BioIndustrial: This industry predominantly consists of enzyme manufacturing and marketing companies. These enzymes are used in industries such as detergents, textiles, food, leather, paper and pharmaceuticals. This generates 6 percent of the revenues of the biotechnology industry.

CONTD…

Biotechnology is expected to offer investment opportunities of Rs. 9-10 billion In the next 5 years and the growth is expected in the following areas:

Vaccines: Vaccines and recombinant therapeutics are the leading sectors driving the growth of the biotechnology industry in India. It is estimated to reach $20 billion in 2012.

Bioactive Therapeutic Proteins: Production of proteins and antibodies and fabrication of diagnostic protein chips would be a promising area for investment.

Stem cell research, cell engineering and cell based therapeutics could be another area where India could cash in its expertise. Up to 25% growth is expected in this field.

Agriculture sector: India has the potential to become a major producer of transgenic rice and several genetically modified (GM) or engineered vegetables by 2010.There is an increasing use of molecular markers in crop breeding and a growing realization that some of these new technologies could lead to future growth in the productivity and quality of crops such as rice, wheat, eggplant (brinjal), tomato and lady’s finger.

TECHNOLOGY

Grew threefold in just five years to report revenues of US$ 3 billion in 2009-10

Rise of 17 per cent over the previous year, according to the eighth annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and a monthly journal.

The biopharma sector contributed nearly three-fifth to the industry's revenues at US$ 1.9 billion, a rise of 12 per cent, followed by bioservices at US$ 573 million and bioagri at US$ 420.4 million. The remaining revenue came from the bioindustrials US$ 122.5 million and bioinformatics US$ 50.2 million segments.

Financial analysis

Biopharma and bioservices sectors contributed 63 per cent and 33 per cent, respectively, to the total biotech exports. The bioagriculture, bioindustrials and bioinformatics sectors remained focussed on domestic operations, bringing in nearly 90 per cent of their revenues from India

Biocon, which has topped the list of biotech companies in India in the ABLE survey, India is looking forward to achieve US$ 5 billion in revenue this fiscal (2010-11).

According to a joint study by an industry body and Ernst and Young (E&Y) released in August 2009, the industry in India have grown by 116 per cent during June 2009 and August 2010.

The country moved from rank 18 to 12 across the 60 most active countries in 2010.

CONTD…

Biocon Serum Institute of India Panacea Biotec Nicholas Piramal Wockhadrt Limited GlaxoSmithKline Bharat Serum Krebs Biochemicals and Industries Limited Zydus Cadila Indian Immunologicals

TOP BIOTECH INDUSTRIES

Biocon was started on 29th November, 1978 in Bangalore. Biocon’s Founding Day - the start of a biorevolution in India. Biocon India is incorporated as a joint venture between Biocon

Biochemicals Ltd. of Ireland and an Indian entrepreneur, Ms.Kiran

Mazumdar-Shaw  It has evolved from an enzyme-manufacturing company into a fully

integrated biopharmaceutical enterprise. Biocon delivers products and solutions to partners and customers in

approximately 75 countries across the globe. Biocon is ranked among the top 20 global biotechnology

companies and the 7th largest biotech employer in the world.

BIOCON

Its mission is to be an integrated biotechnology enterprise of global

distinction. Revenue increased 53% from Rs. 10,902 million to Rs. 16,732 million. Received ISO 9001 accreditation in 1993 and recertification 

for ISO 9001:2008, ISO 14001:2004 certification & OHSAS

18001:2007 certification.

AWARDS Padmashri in 1989 and Padmabhushan in 2005 for pioneering

biotechnology in India. Named among TIME magazine’s 100 most influential people in the

world in 2010

CONTD…

India's No. 1 biotech company with a global ranking of 16 in 2004.

Biocon wins prestigious BioSingapore Asia Pacific Biotechnology Award for Best Listed Company in 2009.

Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector.

Biocon among Top 20 Indian companies in Forbes ‘Best Under A Billion’ list.

CONTD…

Serum Institute of India was founded in 1966 in Pune. SII belongs to the Poonawalla Group. SII is basically an organisation concentrating on vaccines and

other biologicals. SII aims to manufacture life-saving immuno-biologicals, which

were in shortage in the country and imported at high prices. World's largest producer of Measles and DTP group of vaccines. Dr.Cyrus S. Poonawalla, Chairman & MD, SII. Two out of every three children immunized in the world is

vaccinated by a vaccine manufactured by Serum Institute.

SERUM INSTITUTE OF INDIA

SII’s range of products have been used in 140 countries across the globe.

Serum Institute went on to launch, Anti-Snake Venom Serum, Measles, Mumps and Rubella Virus Vaccine, and several other products that attest to its seriousness of purpose. 

SII eliminated India’s dependence on imports for several product lines

The largest supplier for the Government’s Expanded Programme of Immunization.

Nurtured a core group of Biotechnology scientists, which has gained official recognition in International scientific forums.

CONTD…

AWARDS The only private sector manufacturer of vaccines from a developing

nation to be invited to Geneva for WHO’s programme of ‘Children’s Vaccine Initiative’.

Certificate of Merit awarded by CHEMEXCIL, Mumbai, for outstanding export performance in 1994, 1995, 1996, 1997.

Vikas Bharati Award received in 1997 from International Council for Business Promotion for outstanding achievements and contribution in the field.

The Ernst and Young (E&Y) Award for Health and Life Sciences, 2007 being awarded to Dr Cyrus Poonawalla.

Serum Institute of India have recently set up Serum Bio Pharma Park, India's first biotech Special Economic Zone (SEZ).

CONTD…

GlaxoSmithKline is formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000.

Sir Christopher Gent is the Chairman of GSK. GSK moves to its new UK headquarters in Brentford, West

London. Mission Grow a diversified global business. Deliver more products of value. Simplify the operating model. They produce prescription medicines, vaccines and

healthcare products.

GLAXOSMITHKLINE

GSK works as a partner with under-served communities in the developed and developing world supporting programmes that are innovative, sustainable and bring real benefit to these communities.

GSK’s work with communities has been recognised by Business in the Community (BITC) with a CommunityMark, given to companies which are highly involved in community works.

GSK is the first manufacturing company to receive the award. GSK identified that R&D was best done in smaller more productive

units and introduced Centres of Excellence for Drug Discovery (CEDDs), Pioneers in the Quest for New Medicines.

We delivered 1.4 billion vaccine doses in 2009, of which nearly 1 billion were shipped for use in developing countries.

CONTD…

THANK YOU